BFRI Earnings

BFRI reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 6.99M against an estimate of 7.00M, resulting in a -0.17% surprise. The EPS was -0.59, surpassing the expected -0.6 by 1.67%. The stock experienced a -8.59% price change on the earnings day and a -15.76% change over the next five days, reflecting market reactions to the results.

Following BFRI's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -8.59% on the day of the release. Over the subsequent five days, it saw a -15.76% change. Historically, BFRI's stock price tends to shift by an average of 9.08% in the 10 days leading up to earnings and -7.92% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate BFRI's annual revenue to reach 9.10M, while the EPS is projected at -0.18. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BFRI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BFRI's stock price typically moves by 9.08% in the 10 days before its earnings and -7.92% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.18 and revenue of 9.10M.

Biofrontera's earnings call highlights strong revenue growth, record high quarterly revenue, and significant improvements in gross profit margins and net income. The company's strategic initiatives, including product expansion and cost management, are on track, with optimistic guidance for 2026. Despite risks like legal costs and competition, the overall sentiment is positive, supported by improved financial metrics and promising product developments. The lack of concerning responses in the Q&A further solidifies the positive outlook for the stock price over the next two weeks.